Reimbursement is the diligence workstream most deals underweight — and the one that quietly moves valuation. Fulcrum delivers buy-side and sell-side reimbursement diligence, Quality of Reimbursement, and value-creation strategy across the deal lifecycle.
Most transactions evaluate financial statements without fully understanding the contractual and operational drivers behind future reimbursement performance. Fulcrum sits alongside every other diligence advisor — quantifying reimbursement durability, exposing hidden risk, and uncovering the EBITDA and enterprise value the model is missing, for buyers and sellers alike.
The same rigor de-risks a buyer's thesis and defends a seller's valuation. Fulcrum represents financial sponsors, strategic buyers, investment banks, and management teams — with the reimbursement depth traditional diligence lacks.
Confirm that reimbursement is durable, scalable, and competitively positioned — and translate contract-level detail into a defensible value-creation plan before you commit capital.
Identify and capture reimbursement value before you go to market, resolve issues buyers will find, and build a buyer-ready diligence narrative that protects and enhances valuation.
Fulcrum engages across the full arc of a deal — with a clear role on each side at every stage.
An institutional-grade workflow built for the timeline a live transaction demands. Select a phase to expand it.
We evaluate whether a target's reimbursement is durable, scalable, and competitively positioned — and where future opportunity or hidden exposure is hiding.
How Fulcrum instruments a live diligence engagement, so deal teams always know status, risk, and value. Explore a sample view.
Illustrative sample dashboards. The Fulcrum Diligence Tracker is configured to each transaction's workstreams, findings, and value bridge.
Move the sliders to reflect a target across ten reimbursement dimensions. The scorecard computes an overall Quality of Reimbursement score with executive commentary and priority areas.
Rate each dimension from 0 (poor) to 10 (excellent).
Reimbursement improvement can simultaneously grow revenue, expand EBITDA, and materially increase enterprise value — the difference between a good deal and a great one. Model the impact for a target or portfolio company.
Adjust the assumptions — results update live.
Illustrative only. Actual outcomes depend on contract terms, payer mix, utilization, implementation, market dynamics, and operational performance.
Because Fulcrum's engagements are project-based and non-recurring, they are frequently treated as EBITDA add-backs in quality-of-earnings analysis at exit — normalized out of run-rate earnings by the buyer's diligence.
Across engaged portfolio companies that have transacted, our fees were treated as add-backs in the substantial majority of deals — so the investment doesn't dilute the multiple, while the reimbursement value we create flows directly into valuation.
Higher normalized EBITDA → a higher exit multiple applied → better ROI for the fund and its shareholders.
Deep reimbursement expertise wherever the deal is — platforms, add-ons, carve-outs, and recapitalizations.
Accounting and legal diligence are essential — but neither answers whether reimbursement is durable, competitive, and improvable. Fulcrum does, and then executes on it.
Whether you're underwriting a platform, running a sell-side process, or preparing for exit, Fulcrum delivers the reimbursement diligence, analytics, and execution that protect the thesis and move the valuation.